(Q30445633)

21 June 2017

Bevacizumab in combination with irinotecan for patients with recurrent glioblastoma multiforme (English)

1 reference

21 June 2017

1 reference

1 reference

1 reference

David Schiff

1

1 reference

PubMed ID

18285760

21 June 2017

Benjamin Purow

series ordinal

2

1 reference

21 June 2017

19 February 2008

1 reference

Nature Clinical Practice Oncology

21 June 2017

1 reference

21 June 2017

5

1 reference

21 June 2017

4

1 reference

21 June 2017

186-187

1 reference

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

21 June 2017

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1077

7 January 2021

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1077

7 January 2021

MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1077

7 January 2021

Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1077

7 January 2021

Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1077

7 January 2021

Identifiers

DOI

10.1038/NCPONC1077

1 reference

PubMed ID

18285760

Dimensions Publication ID

21 June 2017

0 references

1 reference

PubMed ID

18285760